Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 19.09
+0.65 (3.52%)
At close: Mar 27, 2026
SHE:300497 Revenue
In the year 2025, Jiangxi Fushine Pharmaceutical had annual revenue of 1.18B CNY with 0.61% growth. Jiangxi Fushine Pharmaceutical had revenue of 415.64M in the quarter ending December 31, 2025, with 106.81% growth.
Revenue
1.18B
Revenue Growth
+0.61%
P/S Ratio
8.68
Revenue / Employee
667.97K
Employees
1,774
Market Cap
10.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18B | 7.14M | 0.61% |
| Dec 31, 2024 | 1.18B | -431.82M | -26.83% |
| Dec 31, 2023 | 1.61B | -37.59M | -2.28% |
| Jan 1, 2023 | 1.65B | 217.72M | 15.23% |
| Jan 1, 2022 | 1.43B | -63.41M | -4.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 2.06B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Aurisco Pharmaceutical | 1.62B |
| Liaoning Chengda Biotechnology | 1.39B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Hualan Biological Vaccine | 976.44M |
| Bio-Thera Solutions | 933.69M |
| HitGen | 525.57M |